Genmab A/S (NASDAQ:GMAB) Announces Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Key Points

• Genmab reported quarterly EPS of $0.56, beating the $0.36 consensus by $0.20; revenue of $1.19 billion came in slightly below the $1.20 billion estimate.
• For the first nine months of 2026, revenue grew 22% and adjusted operating profit rose 9%. EPKINLY sales climbed 47% to $491 million, while TIVDAK sales increased 9% to $131 million.
• Genmab maintained its 2026 guidance and expects revenue toward the upper end of its range, while citing three positive Phase III readouts and potential launches beginning in 2027. Management cautioned that fourth-quarter expenses will rise significantly as it prepares for development and launches.

Genmab A/S (NASDAQ:GMAB - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.36 by $0.20, Zacks reports. Genmab A/S had a net margin of 16.97% and a return on equity of 13.96%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.20 billion.

Here are the key takeaways from Genmab A/S's conference call:

• Genmab reported 22% revenue growth for the first nine months of 2026 and 9% growth in adjusted operating profit. Management said growth is becoming more diversified, with roughly half of revenue growth coming from outside DARZALEX.
• Commercial momentum continued: EPKINLY sales rose 47% to $491 million, while TIVDAK sales increased 9% to $131 million. Genmab highlighted broader EPKINLY adoption and continued TIVDAK growth in Japan and Europe.
• The company announced three positive Phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Genmab sees potential launches beginning in 2027, though the medicines remain subject to regulatory review.
• Genmab maintained its 2026 guidance, expects revenue in the upper part of its $4.325–$4.525 billion range, and said adjusted operating profit should finish above the midpoint of its guidance range.
• Management cautioned that fourth-quarter operating expenses will rise significantly due to manufacturing, clinical development, and launch-readiness work for Rina-S and petosemtamab.

Genmab A/S Price Performance

GMAB stock traded up $0.89 on Friday, reaching $53.63. The company had a trading volume of 7,827,783 shares, compared to its average volume of 6,032,240. The company's fifty day moving average is $39.18 and its 200 day moving average is $31.11. The company has a market cap of $33.47 billion, a P/E ratio of 41.25, a PEG ratio of 2.11 and a beta of 0.73. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GMAB. Weiss Ratings upgraded shares of Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. raised shares of Genmab A/S from a "neutral" rating to an "overweight" rating in a report on Monday, October 26th. TD Cowen upped their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a "buy" rating in a research report on Monday, October 26th. Guggenheim increased their target price on shares of Genmab A/S from $58.00 to $80.00 and gave the company a "buy" rating in a report on Friday, October 30th. Finally, Truist Financial reiterated a "buy" rating and set a $67.00 price target (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.